Clinical Trials · NCT03093272
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 9
- Start date
- Jun 2017
- Locations
- 2 sites, United States
- Primary endpoint
- To Evaluate Progression-free Survival on the Combination of Docetaxel Plus Apalutamide